| Primary reference | Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer., LaMarche MJ, Acker MG, Argintaru A, Bauer D, Boisclair J, Chan H, Chen C, Chen YP, Chen Z, Deng Z, Dore M, Dunstan D, Fan J, Fekkes P, Firestone B, Fodor M, Garcia-Fortanet J, Fortin PD, Fridrich C, Giraldes J, Glick M, Grunenfelder D, Hao HX, Hentemann M, Ho S, Jouk A, Kang ZB, Karki R, Kato M, Keen N, Koenig R, LaBonte LR, Larrow J, Liu G, Liu S, Majumdar D, Mathieu S, Meyer M, Mohseni M, Ntaganda R, Palermo M, Perez LB, Pu M, Ramsey T, Reilly J, Sarver P, Sellers WR, Sendzick M, Shultz MD, Slisz J, Slocum K, Smith T, Spence S, Stams T, Straub C, Tamez V, Toure BB, Towler C, Wang P, Wang H, Williams SL, Yang F, Yu B, Zhang JH, Zhu S, J Med Chem. 2020 Sep 10. doi: 10.1021/acs.jmedchem.0c01170. PMID:32910655 |
